by John A. Jenkins | Jan 3, 2024 | FDA, FOIA, Pharmaceuticals
FOIAengine Lines Up the Players in a Huge Patent Fight When the Food and Drug Administration announced three weeks ago the approval of two milestone treatments for sickle cell disease, the agency hailed the action as “an innovative advancement in the field of gene...
by Randy E. Miller | Dec 13, 2023 | FDA, FOIA, Hedge Funds, Pharmaceuticals, Short-Selling, Stock Market
FOIAengine Reveals FOIA Requests About Establishment Labs Food and Drug Administration FOIA records released this month reveal that breast implant manufacturer Establishment Labs (NASDAQ: ESTA), previously targeted by well-known activist short-seller Hindenburg...
by Randy E. Miller | Nov 16, 2023 | FDA, FOIA, Law Firms, Litigation, Pharmaceuticals
FOIAengine Reveals Threat of Litigation Personal injury law firm Morgan & Morgan is gearing up for what could be extensive litigation against the makers of popular weight control drugs. On October 12, the Orlando, Florida-based law firm submitted to the Food and...
by John A. Jenkins | Nov 2, 2023 | FDA, FOIA, Pharmaceuticals
In FOIAengine, Media Requests Seek the Answer When word leaked in late August that the Department of Health and Human Services recommended that marijuana should no longer be considered a dangerous drug, media organizations quickly responded with a flurry of Freedom of...
by John A. Jenkins | Oct 25, 2023 | FDA, FOIA, Litigation, Pharmaceuticals
In FOIAengine, a Slew of Requests About Ivermectin Robert Califf headed up the Food and Drug Administration during the last year of the Obama Administration. By the time Califf spun through the revolving door, returning to his old job early in 2022, he’d picked up...
by Randy E. Miller | Sep 20, 2023 | FDA, FOIA, Hedge Funds, Pharmaceuticals, Short-Selling, Stock Market
FOIAengine Identifies 57 New FOIA Requests to FDA Hedge funds and other financial institutions made 57 Freedom of Information Act (FOIA) requests last month to the Food and Drug Administration (FDA) seeking information about adverse drug events and...
